TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF
The present disclosure relates to a recombinant oncolytic virus useful for inhibiting the growth of or killing tumor cells. More specifically, the recombinant oncolytic virus contains a heterologous nucleic acid sequence encoding an inflammation suppressive gene including, but not limited to, natural killer cell inhibitor, a chemokine binding protein, and an NF-κB inhibitor. Alternatively, the recombinant oncolytic virus contains a two or more heterologous nucleic acid sequences encoding one or more inflammation suppressive genes including, but not limited to, natural killer cell inhibitor(s), one or more chemokine binding protein(s), and/or one or more NF-κB inhibitor(s). Optionally, a recombinant oncolytic virus may further comprise one or more heterologous viral internal ribosome entry site (IRES) that is neuronally-silent. Such recombinant oncolytic viruses can be used to treat singular tumors or multi-focal tumors, such as those found in hepatocellular carcinoma or other cancers.
1 . A recombinant oncolytic virus, comprising an oncolytic virus or a recombinant variant of an oncolytic virus and a heterologous nucleic acid sequence encoding an inhibitor of inflammatory or innate immune cell migration or function, wherein said heterologous nucleic acid sequence is incorporated within the genetic material of said oncolytic virus or recombinant variant of an oncolytic virus.
2 . The recombinant oncolytic virus of claim 1 wherein said oncolytic virus is selected from the group consisting of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), retrovirus, reovirus, measles virus, Sinbis virus, influenza virus, herpes simplex virus, vaccinia virus, and adenovirus.
3 . The recombinant oncolytic virus of claim 1 and wherein said recombinant variant of an oncolytic virus is a recombinant variant of a virus selected from the group consisting of vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), retrovirus, reovirus, measles virus, Sinbis virus, influenza virus, herpes simplex virus, vaccinia virus, and adenovirus.
4 . The recombinant oncolytic virus according to claim 1 wherein said inhibitor of inflammatory cell migration or function is selected from the group consisting of a natural killer cell inhibitor, a chemokine binding protein, and an NF-κB inhibitor.
5 . The recombinant oncolytic virus according to claim 4 wherein said natural killer cell inhibitor, said chemokine binding protein, or said NF-κB inhibitor is a viral protein, a bacterial protein, a fungal protein, a parasitic protein, or a eukaryotic protein.
6 . The recombinant oncolytic virus according to claim 5 wherein said inhibitor of inflammatory cell migration or function is a chemokine binding protein or a truncated variant thereof.
7 .- 15 . (canceled)
16 . The recombinant oncolytic virus according to claim 5 wherein said inhibitor of inflammatory cell migration or function is a natural killer cell inhibitor or a truncated variant thereof.
17 .- 19 . (canceled)
20 . The recombinant oncolytic virus according to claim 5 wherein said inhibitor of inflammatory cell migration or function is an NF-κB inhibitor or a truncated variant thereof.
21 .- 23 . (canceled)
24 . The recombinant oncolytic virus according to claim 1 , further comprising a heterologous viral internal ribosome entry site (IRES) that is neuronally-silent and operably linked to at least one nucleic acid sequence that encodes an oncolytic virus polypeptide.
25 . The recombinant oncolytic virus according to claim 24 wherein the oncolytic virus polypeptide is one or more of an oncolytic virus polymerase, an oncolytic virus structural protein, or an oncolytic virus glycoprotein.
26 . The recombinant oncolytic virus according to claim 24 wherein the recombinant oncolytic virus comprises two or more IRESs and each is operably linked to a different nucleic acid sequence that encodes an oncolytic virus polypeptide.
27 .- 28 . (canceled)
29 . The recombinant oncolytic virus according to claim 24 wherein the IRES is a picornavirus IRES.
30 .- 33 . (canceled)
34 . A recombinant oncolytic virus, comprising an oncolytic virus or a recombinant variant of an oncolytic virus and a heterologous nucleic acid sequence encoding an inhibitor of inflammatory or innate immune cell migration or function, wherein said heterologous nucleic acid sequence is incorporated within the genetic material of said oncolytic virus or recombinant variant of an oncolytic virus, said recombinant oncolytic virus further comprising a heterologous nucleic acid sequence encoding a viral internal ribosome entry site (IRES) that is neuronally-silent and operably linked to a nucleic acid sequence that encodes an oncolytic virus polypeptide.
35 .- 52 . (canceled)
53 . The recombinant oncolytic virus according to claim 34 wherein the recombinant oncolytic virus comprises two or more IRESs and each is operably linked to a different nucleic acid sequence that encodes an oncolytic virus polypeptide.
54 .- 55 . (canceled)
56 . The recombinant oncolytic virus according to claim 34 wherein the IRES is a picornavirus IRES.
57 .- 60 . (canceled)
61 . A method of inhibiting the growth or promoting the killing of a tumor cell, said method comprising the step of contacting said tumor cell with a recombinant oncolytic virus according to claim 1 at a multiplicity of infection sufficient to inhibit the growth or kill the tumor cell.
62 . The method according to claim 61 wherein said tumor cell is selected from the group consisting of a hepatocellular carcinoma (HCC) cell, a colorectal cancer cell, a breast cancer cell, a lung cancer cell, a head and neck cancer cell, a brain cancer cell, a leukemia cell, a prostate cancer cell, a bladder cancer cell, and an ovarian cancer cell.
63 .- 82 . (canceled)
83 . A method of inhibiting the growth or promoting the killing of a tumor cell, said method comprising the step of contacting said tumor cell with a recombinant oncolytic virus according to claim 34 at a multiplicity of infection sufficient to inhibit the growth or kill the tumor cell.
84 . The method according to claim 83 wherein said tumor cell is selected from the group consisting of a hepatocellular carcinoma (HCC) cell, a colorectal cancer cell, a breast cancer cell, a lung cancer cell, a head and neck cancer cell, a brain cancer cell, a leukemia cell, a prostate cancer cell, a bladder cancer cell, and an ovarian cancer cell.